299 related articles for article (PubMed ID: 35676823)
1. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.
Dedrick RM; Smith BE; Cristinziano M; Freeman KG; Jacobs-Sera D; Belessis Y; Whitney Brown A; Cohen KA; Davidson RM; van Duin D; Gainey A; Garcia CB; Robert George CR; Haidar G; Ip W; Iredell J; Khatami A; Little JS; Malmivaara K; McMullan BJ; Michalik DE; Moscatelli A; Nick JA; Tupayachi Ortiz MG; Polenakovik HM; Robinson PD; Skurnik M; Solomon DA; Soothill J; Spencer H; Wark P; Worth A; Schooley RT; Benson CA; Hatfull GF
Clin Infect Dis; 2023 Jan; 76(1):103-112. PubMed ID: 35676823
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium abscessus Strain Morphotype Determines Phage Susceptibility, the Repertoire of Therapeutically Useful Phages, and Phage Resistance.
Dedrick RM; Smith BE; Garlena RA; Russell DA; Aull HG; Mahalingam V; Divens AM; Guerrero-Bustamante CA; Zack KM; Abad L; Gauthier CH; Jacobs-Sera D; Hatfull GF
mBio; 2021 Mar; 12(2):. PubMed ID: 33785625
[No Abstract] [Full Text] [Related]
3. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection.
Nick JA; Dedrick RM; Gray AL; Vladar EK; Smith BE; Freeman KG; Malcolm KC; Epperson LE; Hasan NA; Hendrix J; Callahan K; Walton K; Vestal B; Wheeler E; Rysavy NM; Poch K; Caceres S; Lovell VK; Hisert KB; de Moura VC; Chatterjee D; De P; Weakly N; Martiniano SL; Lynch DA; Daley CL; Strong M; Jia F; Hatfull GF; Davidson RM
Cell; 2022 May; 185(11):1860-1874.e12. PubMed ID: 35568033
[TBL] [Abstract][Full Text] [Related]
4. Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities.
Hatfull GF
Pulm Ther; 2023 Mar; 9(1):91-107. PubMed ID: 36583829
[TBL] [Abstract][Full Text] [Related]
5. Bacteriophage infection and killing of intracellular
Schmalstig AA; Wiggins A; Badillo D; Wetzel KS; Hatfull GF; Braunstein M
mBio; 2024 Jan; 15(1):e0292423. PubMed ID: 38059609
[TBL] [Abstract][Full Text] [Related]
6. Unusual prophages in Mycobacterium abscessus genomes and strain variations in phage susceptibilities.
Amarh ED; Dedrick RM; Garlena RA; Russell DA; Gauthier CH; Aull HG; Abad L; Jacobs-Sera D; Akusobi C; Rubin EJ; Hatfull GF
PLoS One; 2023; 18(2):e0281769. PubMed ID: 36795728
[TBL] [Abstract][Full Text] [Related]
7. Specificity of Immunoglobulin Response to Nontuberculous Mycobacteria Infection in People with Cystic Fibrosis.
Malcolm KC; Wheeler EA; Calhoun K; Lenhart-Pendergrass PM; Rysavy N; Poch KR; Caceres SM; Saavedra MT; Nick JA
Microbiol Spectr; 2022 Aug; 10(4):e0187422. PubMed ID: 35863022
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD010004. PubMed ID: 32521055
[TBL] [Abstract][Full Text] [Related]
9. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.
Dedrick RM; Guerrero-Bustamante CA; Garlena RA; Russell DA; Ford K; Harris K; Gilmour KC; Soothill J; Jacobs-Sera D; Schooley RT; Hatfull GF; Spencer H
Nat Med; 2019 May; 25(5):730-733. PubMed ID: 31068712
[TBL] [Abstract][Full Text] [Related]
10. Considerations for Phage Therapy Against
Senhaji-Kacha A; Esteban J; Garcia-Quintanilla M
Front Microbiol; 2020; 11():609017. PubMed ID: 33537013
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010004. PubMed ID: 28000919
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.
Green SI; Clark JR; Santos HH; Weesner KE; Salazar KC; Aslam S; Campbell JW; Doernberg SB; Blodget E; Morris MI; Suh GA; Obeid K; Silveira FP; Filippov AA; Whiteson KL; Trautner BW; Terwilliger AL; Maresso A
Clin Infect Dis; 2023 Oct; 77(8):1079-1091. PubMed ID: 37279523
[TBL] [Abstract][Full Text] [Related]
13. Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium abscessus Infection.
Poerio N; Riva C; Olimpieri T; Rossi M; Lorè NI; De Santis F; Henrici De Angelis L; Ciciriello F; D'Andrea MM; Lucidi V; Cirillo DM; Fraziano M
Microbiol Spectr; 2022 Feb; 10(1):e0254621. PubMed ID: 35080463
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2014 Dec; (12):CD010004. PubMed ID: 25470304
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Dec; 12():CD010004. PubMed ID: 23235684
[TBL] [Abstract][Full Text] [Related]
16. Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus.
Johansen MD; Alcaraz M; Dedrick RM; Roquet-Banères F; Hamela C; Hatfull GF; Kremer L
Dis Model Mech; 2021 Sep; 14(9):. PubMed ID: 34530447
[TBL] [Abstract][Full Text] [Related]
17. Inhaled Bacteriophage Therapy for Multi-Drug Resistant
Winzig F; Gandhi S; Lee A; Würstle S; Stanley GL; Capuano I; Neuringer I; Koff JL; Turner PE; Chan BK
Yale J Biol Med; 2022 Dec; 95(4):413-427. PubMed ID: 36568830
[TBL] [Abstract][Full Text] [Related]
18. Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden.
Hurst-Hess K; Walz A; Yang Y; McGuirk H; Gonzalez-Juarrero M; Hatfull GF; Ghosh P; Ojha AK
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0016223. PubMed ID: 37154689
[TBL] [Abstract][Full Text] [Related]
19. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.
Koh WJ; Jeong BH; Kim SY; Jeon K; Park KU; Jhun BW; Lee H; Park HY; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Kim H; Kwon OJ
Clin Infect Dis; 2017 Feb; 64(3):309-316. PubMed ID: 28011608
[TBL] [Abstract][Full Text] [Related]
20. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
